Antibacterial activities of amphiphilic cyclic cell-penetrating peptides against multidrug-resistant pathogens
Document Type
Article
Date of Original Version
10-6-2014
Abstract
Multidrug-resistant pathogens have become a major public health concern. There is a great need for the development of novel antibiotics with alternative mechanisms of action for the treatment of life-threatening bacterial infections. Antimicrobial peptides, a major class of antibacterial agents, share amphiphilicity and cationic structural properties with cell-penetrating peptides (CPPs). Herein, several amphiphilic cyclic CPPs and their analogues were synthesized and exhibited potent antibacterial activities against multidrug-resistant pathogens. Among all the peptides, cyclic peptide [R4W4] (1) showed the most potent antibacterial activity against methicillin-resistant Staphylococcus aureus [MRSA, exhibiting a minimal inhibitory concentration (MIC) of 2.67 μg/mL]. Cyclic [R4W4] and the linear counterpart R4W4 exhibited MIC values of 42.8 and 21.7 μg/mL, respectively, against Pseudomonas aeruginosa. In eukaryotic cells, peptide 1 exhibited the expected cell penetrating properties and showed >84% cell viability at a concentration of 15 μM (20.5 μg/mL) in three different human cell lines. Twenty-four hour time-kill studies evaluating [R4W4] with 2 times the MIC in combination with tetracycline demonstrated bactericidal activity at 4 and 8 times the MIC of tetracycline against MRSA (MIC = 0.5 μg/mL) and 2-8 times the MIC against Escherichia coli (MIC = 2 μg/mL). This study suggests that when amphiphilic cyclic CPPs are used in combination with an antibiotic such as tetracycline, they provide significant benefit against multidrug-resistant pathogens when compared with the antibiotic alone.
Publication Title, e.g., Journal
Molecular Pharmaceutics
Volume
11
Issue
10
Citation/Publisher Attribution
Oh, Donghoon, Sun, Amir Nasrolahi Shirazi, Kerry L. Laplante, David C. Rowley, and Keykavous Parang. "Antibacterial activities of amphiphilic cyclic cell-penetrating peptides against multidrug-resistant pathogens." Molecular Pharmaceutics 11, 10 (2014): 3528-3536. doi: 10.1021/mp5003027.